Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dengue virus antigens refer to the protein components of the dengue virus (DENV) that are recognized by the host immune system. DENV is a positive-sense, single-stranded RNA virus belonging to the Flaviviridae family and genus Flavivirus. It is primarily transmitted by Aedes mosquitoes and causes dengue fever, which can progress to severe forms such as dengue hemorrhagic fever or dengue shock syndrome. The antigens are classified into structural (Capsid, pre-membrane/membrane, and envelope proteins) and nonstructural (NS1-NS5) proteins. NS1 is a key diagnostic target, while the E protein is the main target for neutralizing antibodies. There are five serotypes of DENV (DENV-1, DENV-2, DENV-3, DENV-4, and DENV-5).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue Virus Antigen (DENV Antigen).